ANIP · ANI Pharmaceuticals, Inc.
$70.19
-1.78% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$2B
Trailing P/E
15.6
Forward P/E
6.8
Dividend yield
—
Beta
0.45
Avg volume
0M
Employees
1K
Daily Change %
-1.78%
5 Days Change
-0.74%
10 Days Change
-3.48%
30 Days Change
-5.14%
60 Days Change
-13.85%
Month to Day Change
-1.70%
Year to Day Change
-10.44%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ANIP
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-10
Latest call per bank · past 12 months
Barclays
Overweight$100
+39.9% vs priceJP Morgan
Overweight$115
+60.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-10 | Guggenheim | Maintains | Buy | $124 → $119 |
| 2026-08-10 | Canaccord Genuity | Maintains | Hold | $91.00 → $90.00 |
| 2026-07-17 | Canaccord Genuity | Initiates | Hold | $0.00 → $91.00 |
| 2026-07-10 | Guggenheim | Reiterates | Buy | $124 |
| 2026-01-16 | Guggenheim | Maintains | Buy | $115 → $124 |
| 2025-12-09 | Barclays | Initiates | Overweight | $0.00 → $100 |
| 2025-11-10 | Guggenheim | Maintains | Buy | $114 → $115 |
| 2025-10-09 | Truist Securities | Maintains | Hold | $77.00 → $90.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.5% below the 50-day MA ($77.56).
- Price vs 200-day MA: Trading 11.3% below the 200-day MA ($79.14).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.16) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($70.19).
ANIP Price Chart
Loading chart for ANIP…
Fundamentals
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
NBIX
Neurocrine Biosciences, Inc.
$16B 9.4% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.